VolitionRX (NYSEAMERICAN:VNRX) Stock Crosses Below Fifty Day Moving Average – Here’s Why

VolitionRX Limited (NYSEAMERICAN:VNRX)’s stock price passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $0.98 and traded as low as $0.3269. VolitionRX shares last traded at $0.3392, with a volume of 34,943,114 shares trading hands.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Maxim Group reissued a “buy” rating and set a $4.00 price target on shares of VolitionRX in a report on Thursday, June 18th. Benchmark reiterated a “hold” rating on shares of VolitionRX in a research report on Monday, August 17th. Two analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $28.00.

VolitionRX Stock Down 10.3%

The company has a market cap of $6.13 million, a price-to-earnings ratio of -0.12 and a beta of 1.16. The business has a fifty day simple moving average of $0.96 and a 200 day simple moving average of $2.42.

VolitionRX (NYSEAMERICAN:VNRX) last announced its quarterly earnings results on Thursday, August 13th. The medical research company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). The firm had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.41 million. Equities analysts anticipate that VolitionRX Limited will post -2.36 EPS for the current fiscal year.

Institutional Investors Weigh In On VolitionRX

Institutional investors have recently modified their holdings of the company. Jane Street Group LLC purchased a new position in VolitionRX in the 4th quarter valued at approximately $28,000. Virtu Financial LLC boosted its position in VolitionRX by 166.6% during the fourth quarter. Virtu Financial LLC now owns 108,581 shares of the medical research company’s stock worth $28,000 after purchasing an additional 67,848 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in VolitionRX in the fourth quarter valued at $34,000. Northwestern Mutual Wealth Management Co. acquired a new stake in VolitionRX in the second quarter valued at $52,000. Finally, Citadel Advisors LLC grew its holdings in VolitionRX by 70.1% in the third quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock valued at $224,000 after purchasing an additional 135,775 shares during the last quarter. Hedge funds and other institutional investors own 8.09% of the company’s stock.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.